Rocuronium (Sandoz Rocuronium)
Rocuronium
Dezzo Trading 392 (Pty) Ltd
Registration
- Applicant
- Dezzo Trading 392 (Pty) Ltd
- Registrations
- 2
- Schedule source
- Consolidated Schedules 06 July 2026
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Sandoz rocuronium 50 EACH 5,0 ml VIAL CONTAINS ROCURONIUM BROMIDE 50,0 mg | 50 | 43114043/17.1/1140 | Registered | S4 | None |
| Sandoz rocuronium 100 EACH 10,0 ml VIAL CONTAINS ROCURONIUM BROMIDE 100,0 mg | 100 | 43114143/17.1/1141 | Registered | S4 | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Rocuronium bromide
S4: Rocuronium
Consolidated Schedules 06 July 2026, line 7832
Pharmacological class: Peripherally acting muscle relaxants. (class 17.1)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-Hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
Drag to rotate. Structure from PubChem CID 441290.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.